Justin S Cetas, M.D., Ph.D.
- Phone:
- 503-220-8262, Ext. 50820
- Office:
- 503 494-4314
Background
The major focus of Dr. Cetas's laboratory is to understand the effects of subarachnoid hemorrhage on the brainstem and central nervous system and their subsequent role in determining long-term outcomes. Delayed vasospasm is a common and devastating consequence of subarachnoid hemorrhage (SAH) that is poorly understood with few effective treatments. The aim of Dr. Cetas's laboratory research is to identify a novel biomarker for predicting a patient's risk for developing delayed vasospasm and subsequent neurological deficits, as well as a new potential therapeutic target for the medical prevention of delayed vasospasm. Specifically, preliminary data both in animal models and patients of SAH suggest that a group of potent vasodilator metabolites of arachidonic acid (called epoxyeicosatrienoic acids or simply EETs) are linked to the development of vasospasm and may predict its development after SAH. The reasearchers propose to test the hypothesis that EETs levels after SAH correlate with the development of delayed vasospasm and that polymorphisms in the gene EPHX2 (which regulates the metabolism of EETs) correlate with an individual's EETs response. They anticipate that individuals whose EETs levels are elevated after SAH will not go on to develop vasospasm. Furthermore, they predict that those individuals who do not elevate their EETs levels after SAH will have a higher frequency of polymorphisms in the EPHX2 gene.
Selected Publications
"The deleterious effects of methamphetamine use on initial presentation and clinical outcomes in aneurysmal subarachnoid hemorrhage,"
"Steroid psychosis: A review for neurosurgeons,"
"Preoperative identification of the facial nerve in patients with large cerebellopontine angle tumors using high-density diffusion tensor imaging: Clinical article,"
"Response,"
"Response,"
